Webinars and Commercial Conversations — Register Now

Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.

Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers

Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Product Spotlight

Abbott Point of Care

i-STAT 1 analyzer

Company

Abbott Point of Care

Name of instrument

i-STAT 1 analyzer

Contact

Jeff Abney

Email

jeff.abney@abbott.com

City, State

Princeton, NJ

Phone

609-454-9000  

Website

https://www.pointofcare.abbott/us/en/home

Type of instrument

combination chemistry/immunoassay

Operational type/Model type

discrete/handheld

List price/First year sold in U.S.

—/2000

Targeted hospital bed size/Targeted test volume

all/—

Company manufactures instrument

yes (also sold by McKesson, Henry Schein, Medline, Cardinal, Concordance, others)

Other models in this family of analyzers

i-STAT Alinity

No. of units in clinical use in U.S./Outside U.S. (countries)

> 30,000/> 10,000 (Europe, Latin America, Africa, Middle East, Asia Pacific)

Dimensions (H × W × D)/Instrument footprint

9.25 × 3 × 2.85 in./< 1 sq. ft.

Weight empty/Weight fully loaded

< 2 lbs./< 2 lbs.

No. of different measured assays onboard simultaneously

—

No. of user-definable (open chemistry) channels

—

Test throughput per hour/Assay run time

—/2–15 min.

No. of direct ion-selective electrode channels

up to 26

Detection methods

potentiometry, amperometry, conductometry

Stat time until completion/specimen throughput for ion-selective electrode

2 min./20–25

Stat time until completion/specimen throughput for basic metabolic panel

2 min./20–25

Stat time until completion/specimen throughput for complete metabolic panel

—

Typical time delay from ordering stat test until aspiration of sample

none

Fully automated microplate immunoassay system

yes (up to 26 tests per unit)

Methodologies supported

potentiometry, amperometry, conductometry

Separation methodologies

none necessary

Stat time until completion of a ß-hCG test

—

Stat time until completion of a cTn test

10 min.

• Typical time delay from test order to aspiration of sample

none

Approximate No. of tests per reagent set/Reagent type

—/self-contained single use

Reagents refrigerated onboard/Reagents ready to use

no/—

Reagent lot tracking/Reagent inventory

no/no

Reagent form/Reagents barcoded

dry chemistry, liquid chemistry (closed reagent system)/yes

Separate reagent pack for each specimen/for each test run

no/no

Walkaway capability/Walkaway duration

yes/2–10 min. or 1 specimen or up to 13 tests

Design of sample-handling system

—

Uses washable cuvettes/Uses disposable cuvettes

no/no

Min.–max. sample volume that can be aspirated at one time 

17–95 µL

Min. reaction volume/Min. specimen volume/Min. dead volume

—

Dedicated pediatric sample cup

no

Primary tube sampling

no

Accommodates most standard tube sizes/Accepts nonstandard tube sizes

no/no

Pierces caps on primary tubes

no

Protects against probe collision

no

Detects clots/liquid level/short sample

yes/yes/yes

Detection or quantitation for hemolysis, icterus, lipemia, clots

detection for hemolysis, icterus, lipemia, clots

Dilutes patient samples onboard/Susceptibility to carryover

no/—

Automatic rerun capability

no

Sample volume can be diluted to rerun out-of-linear-range high results

no

Sample volume can be concentrated to rerun out-of-linear-range low results

no

Autocalibration/Multipoint calibration supported

yes (calibrants are not stored onboard)/yes (recommended avg. frequency: each test)

Typical calibration frequency for ISE/therapeutic drugs/drugs of abuse/general chemistries/immunoassays

—/—/—/each test/each test

Automatic programmable start/Automatic programmable shutdown

yes/yes

Onboard real-time QC/Onboard software capability to review QC

yes/yes

Supports multiple QC lot numbers per analyte

yes

Waste management

manually by user

Sample barcode-reading capability/Autodiscrimination

yes (Interleaved 2 of 5, Codabar, Code 39, Code 128, EAN-8, EAN-13)/—

Lab can control analyzer from remote computer

yes

Instrument can diagnose its own malfunctions

yes (operator intervention required to order parts)

System malfunctions can be diagnosed via remote monitoring

yes

UPS backup power supply

no

Data-management capability/LIS or EHR systems interfaced

optional add-on/—

LIS interface provided/Bidirectional interface capability

yes (additional cost)/no

Modem servicing provided/Service engineer on-site response time

—/— (product replacement within 24 hrs.)

Mean time between failures

— (displays error codes for troubleshooting)

Average scheduled maintenance time by lab personnel

—

Maintenance records kept onboard for user/vendor

—

Maintenance training demonstration module onboard

—

Training included with purchase/Avg. time for basic user training

—/4 hrs. (at customer site)

Advanced operator training/Extra charge for follow-up or advanced training

yes (at customer site)/no

Warranty provided/Cost of annual service contract (24 h/7 d)

yes (1 year)/—

Distinguishing features (supplied by company)

handheld portable analyzer; unit use system can perform chemistry, blood gas, cardiac marker, hematology, and coagulation tests; CLIA-waived tests, including glucose and creatinine; uses 2–3 drops of whole blood or plasma

Note

all information listed was provided to CAP TODAY in 2025; company did not provide updated information by 2026 entry deadline

More products
in this guide

DxC 500 AU Clinical Chemistry Analyzer
DxC 500i Clinical Analyzer
Pictus 500 (P500)
DS2 Elite Automated ELISA System
Stat Profile Prime Plus
VITROS XT 3400 Chemistry Systems
cobas pure integrated solutions 
B⋅R⋅A⋅H⋅M⋅S KRYPTOR compact PLUS